5 Key Takeaways

• 1

  Amgen reported positive results from a phase 3 trial of subcutaneous teprotumumab (TEPEZZA) for thyroid eye disease (TED).

• 2

  The study achieved a proptosis response of 77% at 24 weeks for subcutaneous TEPEZZA, compared to 19.6% in the placebo group.

• 3

  TEPEZZA is the first approved therapy for TED, with the subcutaneous version offering convenience through biweekly administration.

• 4

  The trial showed significant improvements in secondary endpoints, including Clinical Activity Score and patient-reported quality of life.

• 5

  Safety findings were consistent with IV TEPEZZA, with common adverse events including muscle spasms and mild injection site reactions.